{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:26:54Z","timestamp":1780493214426,"version":"3.54.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.atherosclerosis.2016.11.025","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T16:17:14Z","timestamp":1480004234000},"page":"9-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 Danes without ischemic cardiovascular disease and diabetes in 2004\u20132014"],"prefix":"10.1016","volume":"257","author":[{"given":"Anne","family":"Langsted","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob J.","family":"Freiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.11.025_bib1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.11.025_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2012.05.007","volume":"223","author":"Perk","year":"2012","journal-title":"Atherosclerosis"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2016.11.025_bib3","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of Cardiology (ESC) and the European atherosclerosis society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.11.025_bib4","article-title":"Sekund\u00e6r og prim\u00e6r forebyggelse af koronar hjertesygdom med s\u00e6rligt henblik p\u00e5 dyslipidaemi","author":"F\u00e6rgeman","year":"2000","journal-title":"Dan. Cardiol. Selsk."},{"key":"10.1016\/j.atherosclerosis.2016.11.025_bib5","article-title":"Kliniske retningslinier for forebyggelse af kardiovaskul\u00e6r sygdom i Danmark","author":"Thomsen","year":"2004","journal-title":"Eur. Soc. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.11.025_bib6","article-title":"\u00c6ndringer i kliniske retninglinjer for forebyggelse af kardiovaskul\u00e6r sygdom fra 2003 til 2007","author":"Bang","year":"2009","journal-title":"Dan. Cardiol. Selsk."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2016.11.025_bib7","first-page":"A4470","article-title":"Only a fraction of patients with ischaemic diseases or diabetes are treated to recommended target values for plasma lipids","volume":"59","author":"Siggaard-Andersen","year":"2012","journal-title":"Dan. Med. J."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.11.025_bib8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.atherosclerosis.2016.11.025_bib9","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1001\/jama.2013.5732","article-title":"Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease","volume":"309","author":"Thomsen","year":"2013","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.atherosclerosis.2016.11.025_bib10","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.108.804146","article-title":"Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction","volume":"118","author":"Langsted","year":"2008","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.11.025_bib11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am. J. Cardiol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.11.025_bib12","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.11.025_bib13","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.cjca.2012.05.007","article-title":"Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis","volume":"28","author":"Lemstra","year":"2012","journal-title":"Can. J. Cardiol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.11.025_bib14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.11.025_bib15","first-page":"CD004371","article-title":"Interventions to improve adherence to lipid lowering medication","author":"Schedlbauer","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.11.025_bib16","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1345\/aph.1P150","article-title":"Predictors of nonadherence to statins: a systematic review and meta-analysis","volume":"44","author":"Mann","year":"2010","journal-title":"Ann. Pharmacother."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.11.025_bib17","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","article-title":"Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study","volume":"37","author":"Nielsen","year":"2016","journal-title":"Eur. Heart J."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2016.11.025_bib18","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/eurheartj\/ehr080","article-title":"Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study","volume":"32","author":"Banegas","year":"2011","journal-title":"Eur. Heart J."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016314939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016314939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T21:57:39Z","timestamp":1617487059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915016314939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":18,"alternative-id":["S0021915016314939"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.11.025","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 Danes without ischemic cardiovascular disease and diabetes in 2004\u20132014","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}